According to our (Global Info Research) latest study, the global Thyroid Cancer Testing market size was valued at US$ 2017 million in 2025 and is forecast to a readjusted size of US$ 3451 million by 2032 with a CAGR of 8.0% during review period.
The gross profit margin of major companies in the industry was approximately 45%–65%.
Thyroid Cancer Testing includes diagnostic assays and laboratory methods used to identify, classify, and assess thyroid malignancies and suspicious thyroid nodules. Testing may include cytology-supported molecular assays, gene mutation panels, gene expression classifiers, protein biomarkers, immunoassays, and other molecular diagnostic techniques. These tests support diagnosis, risk stratification, treatment selection, and follow-up and are increasingly used alongside ultrasound, fine-needle aspiration, pathology, and other clinical evaluation methods.
The industrial chain of Thyroid Cancer Testing includes upstream antibodies, primers, probes, sequencing reagents, enzymes, biomarkers, diagnostic instruments, sample-preparation products, and software; midstream covers assay development, diagnostic kit production, laboratory testing, sequencing, molecular analysis, validation, data interpretation, and quality control; downstream applications mainly include hospitals, pathology laboratories, molecular diagnostic laboratories, cancer centers, endocrinology clinics, and research institutions.
Thyroid cancer testing includes diagnostic methods used to identify, characterize, and support clinical management of suspected thyroid malignancies, including cytology, laboratory testing, molecular diagnostics, and related testing technologies. Market demand is supported by increasing detection of thyroid nodules, wider use of imaging examinations, greater awareness of thyroid disease, and growing demand for more accurate differentiation between benign and malignant lesions. Technology development is increasingly focused on molecular biomarkers, mutation analysis, gene-expression profiling, and combined interpretation of multiple diagnostic indicators. Molecular testing is particularly valuable for indeterminate thyroid nodules where conventional cytology cannot provide a definitive diagnosis. Precision oncology and personalized treatment planning also increase demand for more detailed molecular characterization. However, advanced testing costs, differences in clinical guidelines, reimbursement limitations, variable access to molecular diagnostics, and concerns regarding overdiagnosis can constrain market expansion. Future development will emphasize diagnostic accuracy, risk stratification, minimally invasive testing, standardized molecular interpretation, and closer integration of laboratory, imaging, and clinical information.
Report Scope
This report is a detailed and comprehensive analysis for global Thyroid Cancer Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Thyroid Cancer Testing market size and forecasts, in consumption value ($ Million), 2021-2032
Global Thyroid Cancer Testing market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Thyroid Cancer Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Thyroid Cancer Testing market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Thyroid Cancer Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Thyroid Cancer Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Veracyte, Inc., Sonic Healthcare USA, Inc. / ThyroSeq, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., QIAGEN N.V., Abbott Laboratories, Siemens Healthineers AG, Beckman Coulter, Inc., Fujirebio Holdings, Inc., Sysmex Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Thyroid Cancer Testing market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Market segment by Type
Cytology and Histopathology Testing
Molecular Genetic Testing
Protein Biomarker and Immunological Testing
Market segment by Specimen Type
Fine-needle Aspiration Samples
Surgical Tissue Samples
Blood and Other Liquid Samples
Market segment by Turnaround Time
Rapid Testing(≤24 Hours)
Standard Testing(>24 Hours–7 Days)
Extended Testing(>7 Days)
Market segment by Application
Malignancy Diagnosis
Indeterminate Nodule Risk Stratification
Treatment Selection and Recurrence Monitoring
Other
Market segment by players, this report covers
Veracyte, Inc.
Sonic Healthcare USA, Inc. / ThyroSeq
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
QIAGEN N.V.
Abbott Laboratories
Siemens Healthineers AG
Beckman Coulter, Inc.
Fujirebio Holdings, Inc.
Sysmex Corporation
Asuragen, Inc. / Bio-Techne Corporation
Illumina, Inc.
Amoy Diagnostics Co., Ltd.
Burning Rock Biotech Limited
Berry Oncology Corporation
BGI Genomics Co., Ltd.
Sansure Biotech Inc.
Tellgen Corporation
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Thyroid Cancer Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Thyroid Cancer Testing, with revenue, gross margin, and global market share of Thyroid Cancer Testing from 2021 to 2026.
Chapter 3, the Thyroid Cancer Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Thyroid Cancer Testing market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Thyroid Cancer Testing.
Chapter 13, to describe Thyroid Cancer Testing research findings and conclusion.
Summary:
Get latest Market Research Reports on Thyroid Cancer Testing. Industry analysis & Market Report on Thyroid Cancer Testing is a syndicated market report, published as Global Thyroid Cancer Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Thyroid Cancer Testing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.